Unterzeichnung(en)
Übersicht
The project will finance the promoter’s research and development (R&D) expenses for the development of a new cancer treatment. It concerns the clinical programme of a cancer vaccine for indications such as NSCLC (non-small-cell lung cancer), which is the major indication currently investigated, as well as trials for colorectal- , prostate- and breast cancer indications.
It is the objective of this new cancer vaccine to stimulate the body's immune system to identify and destroy cancer cells.
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA) by a competent authority according to the Directive 85/337/EEC, amended by Directives 97/11/EC and 2003/35/EC should not be required.
The promoter is a private company not operating in the utilities sector, and is thus not covered by EU Directives on procurement.